Pharmacy Procedures / Pharmacist Review

A complete F-772 §483.45(b)(1)–(3) pharmacy procedures and pharmacist review of the drug regimen policy plus survey-ready documentation tools for skilled nursing facilities. This template covers the facility-wide pharmacy service organized by a licensed pharmacist, the written pharmacy procedures that govern drug handling from receipt to administration to destruction, the drug regimen review tied into the monthly F-755 cycle but reviewed as a standalone program element under F-772, the in-service and audit infrastructure that keeps the program current across medication changes, vendor transitions, and surveyor review windows, and the surveyor-encounter workflow CMS uses during F-772 investigations.

F-772 is the F-tag surveyors cite when the facility cannot produce a coherent, written pharmacy procedure program that meets the regulatory expectation that a licensed pharmacist organize the facility's drug handling and review the drug regimen at the policy-defined cadence. Under §483.45(b)(1), the facility must provide pharmaceutical services (including procedures that assure the accurate acquiring, receiving, dispensing, and administering of all drugs and biologicals) to meet the needs of each resident. Under §483.45(b)(2), the facility is expected to have a procedurally documented pharmacy program governed by a licensed pharmacist. Under §483.45(b)(3), in conjunction with the F-755 pharmacist-conducted drug regimen review, the pharmacist is expected to provide oversight across the full medication use process. Surveyors test the program as a complete system — written procedures, pharmacist oversight, drug regimen review operation, and incident handling — rather than as isolated records.

The most common citation patterns surveyors document include: written pharmacy procedures that don't reflect current facility operations or that haven't been reviewed in the trailing 12 months, drug regimen review operating without an enforceable cadence or scope, pharmacist oversight of the medication-use process limited to dispensing and not extending to the storage and administration chain, no documented bridge plan when the pharmacy vendor or consultant pharmacist changes, no documented in-service program for nursing or pharmacy support staff covering the procedures, and no documented audit cycle that tests compliance with the procedures across units and shifts. This template gives the licensed pharmacist, the DON, the Staff Development Coordinator, the unit nurse manager, and the facility administrator a single shared paper trail so that the pharmacy program demonstrates all three regulatory legs — written procedures, licensed pharmacist oversight, and operationally embedded drug regimen review — at survey.

CMS guidance (State Operations Manual Appendix PP, F-772) treats the pharmacy program as one of the facility's core programs alongside dietary, nursing, and activities. Surveyors do not separate F-772 from F-755 (drug regimen review), F-754 (unnecessary medications), F-758 (psychotropic medications), or F-761 (labeling and storage); a citation under F-772 frequently pulls citations at the adjacent F-tags. Surveyors will pull the written pharmacy procedures, the licensed pharmacist's record of oversight, the drug regimen review documentation, the controlled substance accountability records, and the QA/QI documentation that ties all of these together. Surveyors will also interview the DON, the consultant pharmacist, the unit nurse manager, and at least one direct-care licensed nurse during the F-772 investigation.

This template is intended for use by the licensed pharmacist who is contractually responsible for organizing the facility's pharmacy services, the Director of Nursing who retains facility accountability for daily medication operations, the Staff Development Coordinator who maintains in-service education for the nursing team and the medication room support staff, the unit nurse manager who supports the unit-level routines, and the facility administrator who is signatory on the pharmacy vendor contract and who retains accountability for contract compliance. The included policy review and audit checklist shall be completed at facility-defined cadence (commonly annually for the written procedures, monthly for the QA review) and at minimum 30 days before any anticipated survey window.

Purpose

The purpose of this policy is to establish a single, defensible, surveyor-reviewable pharmacy program under 42 CFR §483.45(b)(1)–(3) that ties to the F-755 drug regimen review, the F-761 labeling and storage program, the F-758 psychotropic medication framework, and the F-754 unnecessary medications framework. It defines the written procedures, the role and responsibility of the licensed pharmacist, the operational routines that the procedures govern, the in-service program that keeps current staff current and orients new staff, the audit cycle that tests compliance, and the QA/QI integration that closes the feedback loop between the surveyor's expectations and the facility's operations.

Policy

The facility shall provide pharmaceutical services that meet the needs of every resident, organized and overseen by a licensed pharmacist in accordance with 42 CFR §483.45(b)(1)–(3). The facility shall maintain a written set of pharmacy procedures that address the acquiring, receiving, dispensing, administering, storing, accounting for, and destroying of all drugs and biologicals, including controlled substances, emergency medications, and contingency stock. The licensed pharmacist shall review the written procedures at facility-defined cadence, shall update them when regulations, guidelines, or facility operations change, and shall sign off each annual review in writing. The drug regimen review shall be performed by the licensed pharmacist for every resident at facility-defined cadence (target: monthly, matching F-755 expectations). In-service education shall be provided to all nursing staff, medication room support staff, and any other staff with access to medication handling on facility-defined cadence and any time procedures change. Audit results shall be integrated into the QAPI program.

Scope

This policy applies to every phase of the medication-use process from acquisition through destruction in the facility, to every resident receiving medication services, to every staff member handling medications, to the licensed pharmacist, the Director of Nursing, the unit nurse managers, the Staff Development Coordinator, the facility administrator, and the contracted pharmacy vendor. It applies during routine operations, during shifts, during weekends and holidays, during emergency situations, during any medication recall or shortage, and during any documented transition in pharmacy vendor or licensed pharmacist coverage. The policy does not replace clinical judgment by the licensed pharmacist or by the attending physicians, but it does establish the procedural framework within which that clinical judgment operates.

Procedure

Written pharmacy procedures

The facility shall maintain written pharmacy procedures that address the following elements: the process by which new medications are acquired and received from the pharmacy vendor; the process by which medications are dispensed (including unit dose, multi-dose vials, compounded preparations, and PRN medications); the process by which medications are administered (including verification, route, timing, and documentation); the process by which medications are stored (per F-761 labeling and storage program); the process for controlled substance accountability (perpetual inventory, shift reconciliation, discrepancy reporting); the process for emergency medication access (emergency kits, contingency stock, stat orders); the process for medication destruction (discontinued, expired, contaminated, recalled); the process for handling medication recalls; the process for the pharmacist-conducted drug regimen review (per F-755 expectations); and the process for handling medication incidents and reporting to the attending physician and the Director of Nursing.

Licensed pharmacist role

The licensed pharmacist retained by the facility shall be responsible for organizing the facility's pharmaceutical services, for maintaining and updating the written pharmacy procedures, for performing the drug regimen review at facility-defined cadence, for conducting pharmacy-focused in-service education for the nursing and medication support staff, for supporting the DON in QA/QI review of the medication-use process, and for signing off each annual review of the written procedures. The pharmacist shall be licensed in the state where the facility is located, shall have access to each resident's current medical record, and shall not have a self-review conflict between the dispensing function and the review function for the same resident.

Vendor and coverage continuity

Any change in pharmacy vendor or in licensed pharmacist coverage shall be documented with a bridging plan that preserves all expectations of this policy for the duration of any gap. The bridging plan shall identify the covering vendor or pharmacist, the start and expected end date of the gap, and confirmation that no operational routine (drug regimen review, controlled substance reconciliation, emergency kit inspection, medication destruction processing) is missed for any resident. The bridging plan shall be retained in the survey binder.

In-service program

The licensed pharmacist, in coordination with the Staff Development Coordinator, shall provide in-service education to all nursing staff, medication room support staff, and any other authorized access staff on the written pharmacy procedures on facility-defined cadence (commonly annually, at hire, and any time procedures change). In-service education shall include the controlled substance handling routines, the medication storage routines, the medication destruction routine, the recall handling routine, and the pharmacovestigation expectations. Attendance shall be documented in the training file.

Audit and QA/QI integration

The DON and the licensed pharmacist shall jointly conduct the audit of the medication-use process at facility-defined cadence (commonly monthly with quarterly aggregation). The audit shall test written procedure compliance across all units, all shifts, the controlled substance reconciliation status, the drug regimen review currency, the emergency kit inspection currency, the in-service currency for staff with authorized access, and any open corrective actions from the prior audit cycle. Findings shall be reported to the QAPI committee and shall inform the in-service program and the next cycle of written procedure updates.

Incident handling and recall response

Any medication incident (medication error, controlled substance discrepancy, temperature excursion, recall notification, storage failure) shall be documented, investigated by the DON in coordination with the licensed pharmacist and the attending physician as needed, and reported through the facility's occurrence reporting mechanism. Recalls shall be processed with quarantine of affected lots, vendor notification, attending physician notification for any resident receiving an affected medication, and documentation of the disposition for each affected lot.

Operational elements

Integration with adjacent F-tags

This policy shall be operated in coordination with F-754 (unnecessary medications), F-755 (drug regimen review), F-758 (psychotropic medications), and F-761 (labeling and storage). The licensed pharmacist and the DON shall jointly confirm that the documentation chains for each adjacent F-tag are consistent with this policy and with each other. Any conflict between the chains shall be resolved through documentation update before survey entry.

Pharmacy vendor contract alignment

The written pharmacy procedures shall be aligned with the pharmacy vendor contract regarding: the vendor's responsibility for labeling at the point of dispensing; the vendor's responsibility for emergency medication access and contingency stock; the vendor's responsibility for medication destruction services where provided; the vendor's responsibility for participating in medication recall response; and the vendor's responsibility for participating in QA/QI reporting at facility-defined cadence. Any change in the pharmacy vendor contract that affects the written procedures shall trigger an update of both documents under joint sign-off.

Surveyor walk-through preparation

In anticipation of any surveyor walk-through, the DON and the licensed pharmacist shall confirm that: the written pharmacy procedures are current and reflect current facility operations; the licensed pharmacist's oversight record is current; the drug regimen review currency is current for every resident; the controlled substance reconciliation is current; the emergency kit inspection is current; the medication destruction log is current; the in-service attendance is current for staff with authorized access; and the QA/QI summary for the trailing quarter is available for review.

Documentation

Documentation generated under this policy shall include: the written pharmacy procedures with annual sign-off by the licensed pharmacist; the licensed pharmacist's oversight record; the drug regimen review records (linked to the F-755 program); the controlled substance reconciliation logs (linked to the F-761 program); the emergency kit inspection logs; the medication destruction logs; the in-service attendance records; the audit results with corrective action documentation; the QA/QI integration summary; the bridging plan records during any vendor or coverage gap; and the policy and procedure itself. Documentation shall be retained per facility policy (commonly a minimum of one year for operational records and indefinitely for the policy and any incident-related records) and shall be retrievable within surveyor timeframes.

Survey prep checklist

The DON and the licensed pharmacist shall complete a 30-day pre-survey review covering: written procedure currency and current annual sign-off; licensed pharmacist oversight currency; drug regimen review currency under the F-755 program; written procedure compliance across all units and shifts; controlled substance reconciliation currency; emergency kit inspection currency; medication destruction log currency; in-service currency for staff with authorized access; QA/QI summary availability; bridging plan documentation for any vendor or coverage gaps; corrective action status for any identified gap; and the policy and procedure itself. Review findings and corrective action documentation shall be retained in the survey binder for the trailing 12 months.

References

Primary regulatory authority: 42 CFR §483.45(b)(1)–(3) — Pharmaceutical Services. CMS State Operations Manual, Appendix PP — Guidance to Surveyors for Long Term Care Facilities, F-772. American Society of Consultant Pharmacists (ASCP) and American Pharmacists Association (APhA) guidance on pharmaceutical services in skilled nursing facilities. Adjacent regulatory frameworks: §483.45(c)(1)–(4) F-755 Drug Regimen Review; §483.45(g)(1)–(2) F-761 Labeling and Storage of Drugs; §483.45(d)(1)–(5) F-758 Psychotropic Medications; §483.45(a) F-754 Unnecessary Medications. State-specific regulations on pharmacy services in skilled nursing facilities. Facility pharmacy vendor contract and any addenda covering the pharmacy service responsibilities referenced in this policy.